Oops, looks like you need to register to access this feature.
Select “Keep Exploring” to look around Scholars in Medicine. You have full access to all videos and podcasts for a limited time. Registration is provided at no cost exclusively for healthcare providers.
Sign Up or Log In

CAPTOPRIL

Brand and Other Names: CAPOTEN
Mechanism of Action:

Captopril prevents the conversion of angiotensin I to angiotensin II by inhibition of ACE, a peptidyldipeptide carboxy hydrolase. This inhibition has been demonstrated in both healthy human subjects and in animals by showing that the elevation of blood pressure caused by exogenously administered angiotensin I was attenuated or abolished by captopril. In animal studies, captopril did not alter the pressor responses to a number of other agents, including angiotensin II and norepinephrine, indicating specificity of action.

Indications:

Captopril tablets, USP are indicated for the treatment of hypertension.

Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low.

Captopril tablets, USP are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis.

Route: oral
Dose:

The initial dose of captopril tablets, USP is 25 mg b.i.d. or t.i.d. If satisfactory reduction of blood pressure has not been achieved after one or two weeks, the dose may be increased to 50 mg b.i.d. or t.i.d. Concomitant sodium restriction may be beneficial when captopril is used alone.

Adverse Reactions:

Each of the following has been reported in approximately 1 to 2 of 1000 patients and are of uncertain relationship to drug use: renal insufficiency, renal failure, nephrotic syndrome, polyuria, oliguria, and urinary frequency.

The following have been reported in about 0.5 to 2 percent of patients but did not appear at increased frequency compared to placebo or other treatments used in controlled trials: gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, aphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, alopecia, paresthesias.

Contraindication:

Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor).

Do not co-administer aliskiren with captopril in patients with diabetes.

Warnings and Precautions:

Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including captopril) may be subject to a variety of adverse reactions, some of them serious, including the following:

Head and Neck Angioedema, Intestinal Angioedema, Anaphylactoid reactions during desensitization, Anaphylactoid Reactions During Membrane Exposure, Neutropenia/Agranulocytosis, 

Description:

Captopril tablets, USP are a specific competitive inhibitor of angiotensin I-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I to angiotensin II.

See package insert for full prescribing information.